Stephens & Co. Reiterates Overweight on Palvella Therapeutics, Maintains $220 Price Target

Stephens & Co. analyst Sudan Loganathan reiterates Palvella Therapeutics (NASDAQ:PVLA) with a Overweight and maintains $220 price target.